{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:17:15Z","timestamp":1785377835552,"version":"3.55.0"},"reference-count":30,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:p>Axial involvement in patients with psoriatic arthritis (PsA) remains common and can be defined in terms of spinal disease alone or in combination with peripheral manifestations. Diagnosis is based upon inflammatory spinal symptoms or the presence of radiological sacroiliitis and other radiographic signs of spondylitis, or by criteria for axial spondyloarthritis (SpA) defined by ASAS (Assessment of SpondyloArthritis International Society). Although recent data are scarce for efficacy of traditional therapies for axial disease (e.g., nonsteroidal antiinflammatory drugs, methotrexate, etc.), limited data are available for targeted biologics and novel agents. We identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA. This review is an update of the axial PsA section of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).<\/jats:p>","DOI":"10.3899\/jrheum.140877","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T11:18:15Z","timestamp":1414840695000},"page":"2286-2289","source":"Crossref","is-referenced-by-count":28,"title":["Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis"],"prefix":"10.3899","volume":"41","author":[{"given":"Peter","family":"Nash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"key":"2018112909335636000_41.11.2286.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.5.386"},{"key":"2018112909335636000_41.11.2286.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/27.2.133"},{"key":"2018112909335636000_41.11.2286.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.3.135"},{"key":"2018112909335636000_41.11.2286.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101049"},{"key":"2018112909335636000_41.11.2286.5","first-page":"1431","article-title":"Therapies for axial disease in psoriatic arthritis. A systematic review","volume":"33","author":"Nash","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909335636000_41.11.2286.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129726"},{"key":"2018112909335636000_41.11.2286.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151563"},{"key":"2018112909335636000_41.11.2286.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080491"},{"key":"2018112909335636000_41.11.2286.9","first-page":"977","article-title":"The radiological assessment of axial involvement in psoriatic arthritis: A validation study of the BASRI total and the modified SASSS scoring methods","volume":"27","author":"Lubrano","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909335636000_41.11.2286.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"2018112909335636000_41.11.2286.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201844"},{"key":"2018112909335636000_41.11.2286.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"2018112909335636000_41.11.2286.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203697"},{"key":"2018112909335636000_41.11.2286.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq129"},{"key":"2018112909335636000_41.11.2286.15","first-page":"80","article-title":"The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept","volume":"29","author":"Lubrano","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909335636000_41.11.2286.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2018112909335636000_41.11.2286.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2018112909335636000_41.11.2286.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2018112909335636000_41.11.2286.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2018112909335636000_41.11.2286.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"2018112909335636000_41.11.2286.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2018112909335636000_41.11.2286.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"2018112909335636000_41.11.2286.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2018112909335636000_41.11.2286.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"2018112909335636000_41.11.2286.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"issue":"Suppl3","key":"2018112909335636000_41.11.2286.26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/annrheumdis-2012-eular.1849","article-title":"Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl3","key":"2018112909335636000_41.11.2286.27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2012-eular.1852","article-title":"Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized, double-blind, placebo-controlled, international study (ALIGN)","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2018112909335636000_41.11.2286.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145946"},{"key":"2018112909335636000_41.11.2286.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.27383"},{"key":"2018112909335636000_41.11.2286.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.34627"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:34:48Z","timestamp":1746502488000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11,1]]},"published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.3899\/jrheum.140877"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140877","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}